Abstract

The present invention provides a method for predicting the sensitivity of a patient suffering from a cancer disease to DNA methylation inhibitor therapy, which comprises determining in vitro in cancer cells taken from the patient and comparing with values for parent type of cells the level of expression of bromodomain containing genes, and/or the level of expression of other herein listed genes, and/or the level of expression of bromodomain containing proteins, and/or the mutations involving the non-synonymous change in amino acid sequence of bromodomain containing genes, and/or the mutations involving the non-synonymous change in amino acid sequence of other herein listed genes, and/or the half maximal inhibitory concentration (IC50) of the inhibitors of DNA methyltransferase, histone acetyltransferase, histone methyltransferase, histone deacetylases, and/or histone demethylases, wherein the increase in the (IC50) signifies cross-resistance, and/or the half maximal inhibitory concentration (IC50) of a selective BET bromodomain inhibitor, wherein the decrease in the (IC50) signifies sensitivity. The invention further provides a combination therapy for cancers using bromodomain inhibitors in combination with DNA methylation inhibitors. ˙


Claims
Download PDF
Document Preview
Document History
  • Publication: Oct 1, 2015
  • Application: Mar 27, 2015
    WO CZ 2015000029 W
  • Priority: Mar 27, 2014
    EP EP 14161897 A

Download Citation


Sign in to the Lens

Feedback